February 13, 2020
Bayer Yakuhin announced on February 12 the results from a PIV study, which evaluated extended treatment intervals for the anti-VEGF inhibitor Eylea (aflibercept) in patients with wet age-related macular degeneration (AMD), showing that at Week 96, up to 60% of...read more